Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death

BACKGROUND: Sorafenib (Sor) is the only approved multikinase inhibitor indicated for the treatment of HCC. Previous studies have shown that amygdalin (Amy) possesses anticancer activities against several cancer cell lines; we suggested that these compounds might disrupt AMPK/mTOR and BCL-2. Therefor...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Sewedy, Tarek, Salama, Afrah Fatthi, Mohamed, Amro E., Elbaioumy, Nashwa M., El-Far, Ali H., Albalawi, Aisha Nawaf, Elmetwalli, Alaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508032/
https://www.ncbi.nlm.nih.gov/pubmed/37726740
http://dx.doi.org/10.1186/s12906-023-04142-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508032/
https://www.ncbi.nlm.nih.gov/pubmed/37726740
http://dx.doi.org/10.1186/s12906-023-04142-1

Ejemplares similares